Rhode Island Senate Bill S2890

Rhode Island 2026 Regular Session

• Introduced: 3/4/26
• Refer: 3/4/26

Caption

Mandates health insurance coverage for medically necessary hormonal/non-hormonal therapy to treat symptoms of peri-menopause/menopause, if therapy is recommended by qualified healthcare provider licensed in RI and has proven safe and effective.

Impact

The enactment of S2890 intends to enhance women’s access to necessary medical treatments associated with menopause. By mandating insurance coverage, the bill aims to alleviate the financial burden of these treatments, which can be significant given the varying costs of hormone therapies. The inclusion of FDA-approved modalities, which encompass options such as oral, transdermal, topical, and vaginal hormonal administration, reflects a comprehensive approach to addressing menopausal symptoms. This amendment seeks to solidify women's health rights in insurance coverage, making it more equitable and aligned with medical necessity standards.

Summary

Senate Bill S2890 mandates that group health insurers in Rhode Island must provide coverage for medically necessary hormone and non-hormonal therapy treatments to address menopausal symptoms. This requirement applies to any insurance policy issued, amended, or renewed on or after January 1, 2027. The bill specifically highlights the need for therapies recommended by qualified healthcare providers who are licensed in Rhode Island. Additionally, it underlines that the therapies must be proven safe and effective in peer-reviewed studies, ensuring that the treatment prescribed is of an established standard.

Contention

Some notable points of contention surrounding the bill may arise from discussions regarding insurance costs and the potential financial implications for insurers and policyholders. Critics may argue that mandating coverage for hormone treatments could result in increased insurance premiums, which could affect affordability. Supporters, however, emphasize the importance of ensuring women's healthcare needs are prioritized, promoting health equity and access to essential services. Moreover, the requirement for treatments to be validated by the medical community could spark debates regarding the definition of 'medically necessary' and how it is interpreted by different insurance providers.